GLP-1 Precautions for Using the GLP-1 program The GLP-1 program works by assisting the pancreas in regulating and reducing blood sugar levels
39 Although GLP-1RAs continue to be promising therapies for T2D, their long-term efficacy for weight loss after halting treatment should be further improved
Large trials randomising tens of thousands of patients would be required to accurately detect an effect of GLP-1RA on SIS risk
For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)